Sponsor study identifier
interventional
150
1 country
7
Study Start
February 23, 2026
Actual (reported)Primary Completion
February 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
February 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The are doing this study to find out whether using topical (on the skin) herbal plasters, Tibetree pain- relieving plasters (PRPs), can be an effective addition to standard opioid therapy for pain management. The researchers will look at whether the Tibetree PRPs are a practical (feasible) and effective way of managing localized pain (pain that is limited to a certain area) in people who are currently taking opioids. Participants in this study will have cancer or have had it in the past.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 23, 2026
Actual (reported)February 25, 2026
Actual (reported)March 4, 2026
Actual (reported)February 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
February 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Enrollment rate
This is the proportion of patients who enroll in the study among those who are eligible and offered participation.
2 years
Treatment adherence rate
The treatment adherence rate is defined as the proportion of patients who are in the intervention period (both arms) who complete at least 5 of the 7 days of herbal plaster application.
2 years
Assessment completion rates
The proportion of randomized patients who complete the patient-reported assessments.
2 years
Will use the Tibetree PRPs on Days 1-7 of the treatment period.
Will use the Tibetree PRPs on Days 8-14 of the treatment period after a 7-day waiting period
Participants will receive topical herbal plaster once a day for up to 8 hours daily for 7 days.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, New Jersey, 07748, United States
Jun Mao, MD, MSCE
Memorial Sloan Kettering Cancer Center
First Submitted
February 25, 2026
First Posted
March 4, 2026
Study Start
February 23, 2026
Actual (reported)Primary Completion
February 2028
Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia
Treatment satisfaction
will be measured on Day 7 of the intervention period. Satisfaction will be measured using two questions with five-point Likert-type response scales to assess overall satisfaction with integrating the patch into their opioid pain management plan and their willingness to recommend it to other patients. Patients will be considered "satisfied" with the treatment if they respond as "Satisfied" or "Very satisfied" to the satisfaction item
day 7
pain severity
up to day 7
Contact the study team to confirm eligibility.
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities)
Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York, 10604, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065, United States
Memorial Sloan Kettering Nassau (All Protocol Activities)
Rockville Centre, New York, 11553, United States
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
February 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
March 4, 2026
Record last verified: 2026-02
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: